IDRA News and Press, Idera Pharmaceuticals Inc. From 06/22/21

vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera Pharmaceuticals (IDRA) +11%.Insp...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning! We’re taking a look at the biggest pre-market stock movers for Tuesday as the perfect way to start the day. Source: Eric Urquhart/Shutterstock.com Also, if you’re interested in catching u...

Senseonics Holdings SENS +34% on the study results for glucose monitoring system.Windtree Therapeutics (WINT) +28%.The9 Limited NCTY +18% on Montcrypto acquisition.SemiLEDs Corporation (LEDS) +16%.Q&K International Group Limited (QK) +15%.Core Laboratories N.V. (CLB) +...

Idera Pharmaceutical (IDRA) has added ~7.6% in the post-market after the company issued a regulatory filing to disclose an insider purchase by Michael Dougherty, the chair of the Board.On a transaction dated June 01, Mr. Dougherty has purchased 85K shares at $1.19 api...

Microcap clinical-stage company Idera Pharmaceuticals (IDRA) is trading ~5.7% lower today after announcing that the company will not continue the ILLUMINATE-301 trial citing its failure to meet the primary endpoint.The Phase 3 trial was designed to compare the combination of tilsoto...

EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimuma...

EXTON, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended March 31, 2021. “Despite the disappointing objective...

Shares of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded at a new 52-week low today of $1.04. Approximately 6.3 million shares have changed hands today, as compared to an average 30-day volume of 5.5 million shares. Idera Pharmaceuticals Inc is a clinical-stage biopharmaceutical company...

Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded at a new 52-week low today of $1.13. Approximately 6.3 million shares have changed hands today, as compared to an average 30-day volume of 5.5 million shares. Idera Pharmaceuticals Inc. (NASDAQ:IDRA) has potential upside of 13.8% based on a...

Shares of Idera Pharmaceuticals Inc. (NASDAQ:IDRA) traded today at $1.12, breaking its 52-week low. This new low was reached on approximately average trading volume as 6.3 million shares traded hands, while the average 30-day volume is approximately 5.5 million shares. Idera Pharmaceutic...